Altium Capital Management LLC Takes Position in Alpha Cognition, Inc. (NASDAQ:ACOG)

Altium Capital Management LLC acquired a new stake in shares of Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 275,000 shares of the company's stock, valued at approximately $1,620,000. Altium Capital Management LLC owned approximately 1.72% of Alpha Cognition as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. National Bank of Canada FI acquired a new position in Alpha Cognition in the fourth quarter worth $69,000. Aristides Capital LLC bought a new stake in shares of Alpha Cognition during the 4th quarter valued at about $1,178,000. ADAR1 Capital Management LLC acquired a new stake in Alpha Cognition during the fourth quarter worth about $1,204,000. Finally, Rosalind Advisors Inc. bought a new position in Alpha Cognition in the fourth quarter worth about $1,489,000.

Alpha Cognition Trading Up 14.5 %

Shares of NASDAQ ACOG traded up $0.66 during midday trading on Wednesday, reaching $5.22. The company's stock had a trading volume of 90,027 shares, compared to its average volume of 78,884. The stock has a market capitalization of $83.62 million, a P/E ratio of -2.04 and a beta of 2.50. Alpha Cognition, Inc. has a one year low of $3.75 and a one year high of $7.00. The stock has a 50 day moving average price of $5.24.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03).

Wall Street Analysts Forecast Growth

ACOG has been the topic of a number of research reports. Raymond James upgraded Alpha Cognition to a "moderate buy" rating in a research report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alpha Cognition in a report on Monday, March 31st.

Alpha Cognition Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.